Shude Cui

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

Zefei Jiang, Wei Li, Xichun Hu et al. · The Lancet Oncology · 2019 · 261 citations

Breast Oncology, Medicine, Pharmacology +8

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

Zhimin Shao, Da Pang, Hongjian Yang et al. · JAMA Oncology · 2019 · 184 citations · Full text

A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy

Qin Li, CHENG-ZHENG WANG, Huijie Fan et al. · Oncology Letters · 2014 · 103 citations · Full text

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

Junjie Li, Ke‐Da Yu, Da Pang et al. · Journal of Clinical Oncology · 2020 · 103 citations · Full text

Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial

Peng Yuan, Xichun Hu, Tao Sun et al. · European Journal of Cancer · 2019 · 86 citations